AU · rank #14 · 2026-07-23
NUTX
NASDAQ · $1.12B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.726 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.58 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.197 |
| Analyst upside Consensus target $246.40 | +56.7% |
| Momentum acceleration 3-month minus 12-month momentum. | +27.94% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.67 |
| Gross margin TTM | +50.6% |
| 52w high | $204.00 |
| Market cap (USD) | $1.12B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Nutex Health Inc (NUTX) is a physician-led healthcare provider operating approximately 27 micro-hospitals and outpatient departments alongside a population health management division [RECENT_DEVELOPMENTS, BUSINESS_STATUS].
Rationale
The massive upward EPS estimate revisions and 56.7% analyst upside signal are supported by Q1 2026 earnings doubling to a diluted EPS of $6.52, driving strong upward target momentum [RECENT_DEVELOPMENTS].
Material risks
- 1Substantial operational reliance on No Surprises Act IDR arbitration for billing disputes, which introduces timing delays, reimbursement uncertainty, and has already pressured EBITDA due to high administrative expenses [RECENT_DEVELOPMENTS].
- 2Capital and liquidity pressure from transitioning to internal funding for new micro-hospital construction ahead of completing anticipated sale-leaseback transactions [RECENT_DEVELOPMENTS].
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.